CompletedNot Applicable

Pharmacokinetic of Thoracic Paravertebral Ropivacaine

Greece20 participantsStarted 2019-10-08

Plain-language summary

The study aims to investigate the pharmacokinetic of ropivacaine in patients undergoing ultrasound guided thoracic paravertebral block (TPVB) both after a single-bolus injection via the thoracic paravertebral catheter given before the start of surgery and after continuous thoracic paravertebral infusion that will start after the end of the procedure in order to achieve postoperative analgesia after open thoracotomy during the first 3 postoperative days

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>18 years * ASA I-III * Open thoracotomy Exclusion Criteria: * Patient refusal * Age \<18 years * Morbid obesity * Scoliosis * Previous thoracotomy * Empyema * Drug allergy * Severe systemic disease * ASA \> III * Hypoalbuminemia * Urgent surgery * Reoperation during the study period

What they're measuring

ropivacaine plasma levels

Timeframe: up to 72 postoperative hours after the initiation of continuous thoracic paravertebral infusion of ropivacaine

Trial details

NCT IDNCT03721406

SponsorAttikon Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-25

View on ClinicalTrials.gov More Open Thoracotomy trials